Every Form 4 that HEPION PHARMS INC (HEPA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HEPA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HEPA filings page.
Hepion Pharmaceuticals, Inc. (HEPA) reported that director Michael J. Purcell received a grant of stock options on August 19, 2026 to acquire 299,000 shares of common stock at an exercise price of $0.08 per share. These options become exercisable on August 19, 2027 and expire on August 19, 2036, leaving him with 299,000 options held directly after the award. No Rule 10b5-1 trading plan is reported for this grant.
Hepion Pharmaceuticals, Inc. (HEPA) reported that Interim CEO and director Gary S. Stetz received a grant of stock options for 1,345,500 shares of common stock. The options have an exercise price of $0.08 per share and expire on August 19, 2036. According to the grant terms, 336,375 options vest immediately, and the remaining options vest in equal monthly installments over six months from the grant date.
Hepion Pharmaceuticals, Inc. (HEPA) reported that Executive Chairman Vincent S. LoPriore received a grant of stock options on 2026-08-19. The award covers 1,345,500 options to acquire common stock at an exercise price of $0.08 per share, expiring on 2036-08-19. According to the footnote, 336,375 options vest upon grant and the remaining options vest in equal monthly installments over six months from the grant date. Following this grant, LoPriore holds 1,345,500 stock options directly.
Hepion Pharmaceuticals, Inc. (HEPA) reported that director and officer Chase LoPriore, VP, Corp. Dev., received a grant of stock options for 1,345,500 shares of Common Stock on August 19, 2026. The options have a conversion or exercise price of $0.08 per share and expire on August 19, 2036. According to the vesting terms, 336,375 options vest upon grant and the remaining options vest in equal monthly installments over six months from the grant date. Following this grant, LoPriore holds 1,345,500 stock options directly.
Hepion Pharmaceuticals, Inc. (HEPA) reported that director Danina Fisher received a grant of stock options to acquire 299,000 shares of common stock. The options have an exercise price of $0.08 per share, become exercisable on August 19, 2027, and expire on August 19, 2036. Following this grant, Fisher holds 299,000 derivative securities directly.
Hepion Pharmaceuticals, Inc. (HEPA) reported that director James Gordon Liddy received a grant of stock options. The award covers 299,000 stock options, each for one share of common stock, with an exercise price of $0.08 per share, exercisable from August 19, 2027 until August 19, 2036. Following this grant, he holds 299,000 stock options directly.
Hepion Pharmaceuticals, Inc. (HEPA) reported that Chief Operating Officer and director Appajosyula Sireesh received a grant of stock options for 1,345,500 shares of Common Stock on 2026-08-19. The options have a conversion/exercise price of $0.08 per share, expire on 2036-08-19, and are held directly. According to the vesting terms, 336,375 options vest upon grant and the remaining options vest in equal monthly installments over 6 months from the grant date, leaving Sireesh with 1,345,500 options outstanding following this award.
Hepion Pharmaceuticals, Inc. (HEPA) reported that director Gary S. Stetz II received a grant of 299,000 stock options on August 19, 2026. The options have an exercise price of $0.08 per share, are exercisable beginning August 19, 2027, and expire on August 19, 2036. Following this grant, he holds 299,000 derivative securities directly.
Hepion Pharmaceuticals, Inc. director Gary S. Stetz II reported net purchases on August 3, 2026. He acquired 500,000 shares of Common Stock at a price of $0.05 per share, bringing his direct Common Stock holdings to 500,000 shares. He also acquired warrants for 500,000 shares of Common Stock with an exercise price of $0.06 and an expiration date of August 3, 2031, resulting in 500,000 warrants held directly. The Rule 10b5-1 checkbox was not marked, indicating these purchases were not reported as made under a trading plan.
Hepion Pharmaceuticals, Inc. reporting person Gary S. Stetz, Interim CEO and director, reported two purchases on August 3, 2026. He acquired 2,000,000 warrants, each exercisable at $0.06 per share into common stock until August 3, 2031. He also purchased 2,000,000 shares of common stock at $0.05 per share, bringing his directly held common stock position to 3,250,000 shares.
Hepion Pharmaceuticals director Michael J. Purcell reported significant insider purchases. On 2026-08-03, he bought 2,000,000 shares of common stock at $0.05 per share, increasing his direct common stock holdings to 3,250,000 shares. He also purchased 2,000,000 warrants with an exercise price of $0.06 per share, exercisable into 2,000,000 common shares and expiring on 2031-08-03, leaving him holding 2,000,000 warrants after the transaction.
Hepion Pharmaceuticals, Inc. director and Chief Operating Officer Sireesh Appajosyula reported insider purchases on 2026-08-03. He acquired 2,000,000 common shares at $0.05 per share and 2,000,000 warrants with a $0.06 exercise price, expiring 2031-08-03. Following these trades, he directly owns 3,250,000 common shares and 2,000,000 warrants. The filing indicates these transactions were not made under a Rule 10b5-1 trading plan.
Hepion Pharmaceuticals Executive Chairman Vincent S. LoPriore, through entities he controls, reported purchases totaling 20,000,000 HEPA-related securities on August 3, 2026. Gravitas Capital LP and Invictus Capital Advisors Pension Plan bought 10,000,000 warrants with a $0.06 exercise price and 10,000,000 common shares at $0.05 per share, all held as indirect ownership.
Hepion Pharmaceuticals director Michael J. Purcell bought 1,250,000 shares of common stock in an open-market purchase. He paid $0.04 per share, for a total of about $50,000. Following this transaction, he directly owns 1,250,000 Hepion Pharmaceuticals common shares.
Hepion Pharmaceuticals, Inc. reported insider-related buying of its common stock. Entities associated with Executive Chairman and 10% owner Vincent S. LoPriore completed open-market purchases at $0.04 per share on April 21, 2026.
Invictus Capital Advisors Pension Plan bought 1,250,000 shares, bringing its holdings to 6,250,000 shares, while Gravitas Capital LP bought 5,000,000 shares, resulting in 5,000,000 shares held. Footnotes state Mr. LoPriore has voting and investment power over both entities’ positions.
Hepion Pharmaceuticals director Appajosyula Sireesh bought 1,250,000 shares of common stock in an open-market transaction at $0.04 per share. Following this purchase on April 21, 2026, he holds 1,250,000 shares directly, indicating a newly established reported ownership position.
Hepion Pharmaceuticals interim CEO Gary S. Stetz reported an indirect open-market purchase of 1,250,000 shares of common stock at $0.04 per share. The shares are held through the Stetz Belgiovine CPA 401K F/B/O Gary S. Stetz account, and this filing shows total indirect holdings of 1,250,000 shares after the transaction.